Pemvidutide

Investigated uses

• Obesity and metabolic dysfunction-associated steatohepatitis in clinical development.

Mechanism and hypotheses

• Pemvidutide is a peptide-based dual GLP-1 and glucagon receptor agonist in clinical development.

Human evidence

• The randomized Phase 2 MOMENTUM trial evaluated pemvidutide in adults with obesity or overweight. Limitations: Later-stage confirmation and regulatory review remain pending.

Safety highlights

• The adverse-event profile remains investigational and formulation-specific prescribing information does not exist.
• Long-term and uncommon risks are not established because no approved label or postmarketing record exists.

Regulatory context

Investigational; no FDA-approved pemvidutide product.